PortalPublikationenScreening for Fatal Traumatic Brain Injuries in Cerebrospina...

Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays

Standard

Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays. / Zwirner, Johann; Anders, Sven; Bohnert, Simone; Burkhardt, Ralph; Da Broi, Ugo; Hammer, Niels; Pohlers, Dirk; Tse, Rexson; Ondruschka, Benjamin.

in: BIOMOLECULES, Jahrgang 11, Nr. 7, 20.07.2021, S. 1061.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Zwirner, J, Anders, S, Bohnert, S, Burkhardt, R, Da Broi, U, Hammer, N, Pohlers, D, Tse, R & Ondruschka, B 2021, 'Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays', BIOMOLECULES, Jg. 11, Nr. 7, S. 1061. https://doi.org/10.3390/biom11071061

APA

Zwirner, J., Anders, S., Bohnert, S., Burkhardt, R., Da Broi, U., Hammer, N., Pohlers, D., Tse, R., & Ondruschka, B. (2021). Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays. BIOMOLECULES, 11(7), 1061. https://doi.org/10.3390/biom11071061

Vancouver

Zwirner J, Anders S, Bohnert S, Burkhardt R, Da Broi U, Hammer N et al. Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays. BIOMOLECULES. 2021 Jul 20;11(7):1061. https://doi.org/10.3390/biom11071061

Bibtex

@article{f96f28c4add74b919f42ced42fc6e787,
title = "Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays",
abstract = "A single, specific, sensitive biochemical biomarker that can reliably diagnose a traumatic brain injury (TBI) has not yet been found, but combining different biomarkers would be the most promising approach in clinical and postmortem settings. In addition, identifying new biomarkers and developing laboratory tests can be time-consuming and economically challenging. As such, it would be efficient to use established clinical diagnostic assays for postmortem biochemistry. In this study, postmortem cerebrospinal fluid samples from 45 lethal TBI cases and 47 controls were analyzed using commercially available blood-validated assays for creatine kinase (CK) activity and its heart-type isoenzyme (CK-MB). TBI cases with a survival time of up to two hours showed an increase in both CK and CK-MB with moderate (CK-MB: AUC = 0.788, p < 0.001) to high (CK: AUC = 0.811, p < 0.001) diagnostic accuracy. This reflected the excessive increase of the brain-type CK isoenzyme (CK-BB) following a TBI. The results provide evidence that CK immunoassays can be used as an adjunct quantitative test aid in diagnosing acute TBI-related fatalities.",
author = "Johann Zwirner and Sven Anders and Simone Bohnert and Ralph Burkhardt and {Da Broi}, Ugo and Niels Hammer and Dirk Pohlers and Rexson Tse and Benjamin Ondruschka",
year = "2021",
month = jul,
day = "20",
doi = "10.3390/biom11071061",
language = "English",
volume = "11",
pages = "1061",
journal = "BIOMOLECULES",
issn = "2218-273X",
publisher = "Multidisciplinary Digital Publishing Institute",
number = "7",

}

RIS

TY - JOUR

T1 - Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays

AU - Zwirner, Johann

AU - Anders, Sven

AU - Bohnert, Simone

AU - Burkhardt, Ralph

AU - Da Broi, Ugo

AU - Hammer, Niels

AU - Pohlers, Dirk

AU - Tse, Rexson

AU - Ondruschka, Benjamin

PY - 2021/7/20

Y1 - 2021/7/20

N2 - A single, specific, sensitive biochemical biomarker that can reliably diagnose a traumatic brain injury (TBI) has not yet been found, but combining different biomarkers would be the most promising approach in clinical and postmortem settings. In addition, identifying new biomarkers and developing laboratory tests can be time-consuming and economically challenging. As such, it would be efficient to use established clinical diagnostic assays for postmortem biochemistry. In this study, postmortem cerebrospinal fluid samples from 45 lethal TBI cases and 47 controls were analyzed using commercially available blood-validated assays for creatine kinase (CK) activity and its heart-type isoenzyme (CK-MB). TBI cases with a survival time of up to two hours showed an increase in both CK and CK-MB with moderate (CK-MB: AUC = 0.788, p < 0.001) to high (CK: AUC = 0.811, p < 0.001) diagnostic accuracy. This reflected the excessive increase of the brain-type CK isoenzyme (CK-BB) following a TBI. The results provide evidence that CK immunoassays can be used as an adjunct quantitative test aid in diagnosing acute TBI-related fatalities.

AB - A single, specific, sensitive biochemical biomarker that can reliably diagnose a traumatic brain injury (TBI) has not yet been found, but combining different biomarkers would be the most promising approach in clinical and postmortem settings. In addition, identifying new biomarkers and developing laboratory tests can be time-consuming and economically challenging. As such, it would be efficient to use established clinical diagnostic assays for postmortem biochemistry. In this study, postmortem cerebrospinal fluid samples from 45 lethal TBI cases and 47 controls were analyzed using commercially available blood-validated assays for creatine kinase (CK) activity and its heart-type isoenzyme (CK-MB). TBI cases with a survival time of up to two hours showed an increase in both CK and CK-MB with moderate (CK-MB: AUC = 0.788, p < 0.001) to high (CK: AUC = 0.811, p < 0.001) diagnostic accuracy. This reflected the excessive increase of the brain-type CK isoenzyme (CK-BB) following a TBI. The results provide evidence that CK immunoassays can be used as an adjunct quantitative test aid in diagnosing acute TBI-related fatalities.

U2 - 10.3390/biom11071061

DO - 10.3390/biom11071061

M3 - SCORING: Journal article

C2 - 34356685

VL - 11

SP - 1061

JO - BIOMOLECULES

JF - BIOMOLECULES

SN - 2218-273X

IS - 7

ER -